Topic: authorized generics
When PDL BioPharma’s blood-pressure medicine faced the threat of a generic rival this year, the company used its own generic to fend off competitors.
Lilly could relieve itself of some public pressure with the authorized Humalog generic, but will Sanofi and Novo follow with Lantus and NovoLog?
The move comes as Lilly and the other two big diabetes drugmakers face increasing political pressure on rising insulin prices.
Years after Teva entered an FTC settlement on "pay-for-delay" deals, the parties on Tuesday expanded the agreement.
Thanks to high rebates and payer hardball, Gilead is in a tough spot with its hepatitis C drugs, including its all-genotype treatment Epclusa and the once-high-flying Harvoni. In response, the company did something previously unheard of in pharma.
Gilead and Express Scripts have clashed in hepatitis C before, but now that Gilead plans authorized generics of its own drugs, Express Scripts is on board.
Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.
After the big EpiPen price-hike outcry last year, Mylan rolled out an authorized generic and talked up its access programs. But it was too little too late, judging from a new report.
EpiPen is set for a substantial sales decline through 2018—to $300 million from last year's $1.1 billion—a leading biopharma analyst figures.